Highest-materiality recent filing
Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.
ProPhase Labs secures $10M equity line facility with Generating Alpha Ltd
Stock Purchase Agreement with Generating Alpha Ltd provides up to $10M equity capital at Company's election.
Over $3.3 million of convertible debt converted from $3.8 million principal, reducing indebtedness and increasing equity; remaining unconverted principal less than $500,000.
Nasdaq staff determination on Dec 29, 2025: company failed to regain compliance with minimum $1.00 bid price rule after two 180-day periods ending Dec 22.
ProPhase Labs signs non-binding LOI for reverse merger with ABL, ABL to become majority owner
ProPhase Labs (PRPH) entered a non-binding LOI for a reverse merger with Advanced Biological Laboratories S.A. (ABL), a European biotech firm.
ProPhase Labs to effect 1-for-10 reverse stock split to maintain Nasdaq listing
Stockholders approved reverse stock split on Nov 24, 2025; board approved Nov 30, 2025.
Judgment entered on Nov 5, 2025 in Utah for Avtech equipment lease; company received it on Nov 19, 2025.
ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M
Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M
ProPhase Labs engages ThinkEquity for $6M private placement; crypto treasury strategy
Exclusive strategic advisory and placement agent agreement for proposed $6M private placement of securities on best efforts basis.
ProPhase Labs shareholders approve share increase to 1B and equity plans
Shareholders approved increase in authorized common shares from 50M to 1B at Sept 9 special meeting.
ProPhase Labs terminates $7.7M equity line with Keystone Capital Partners
Terminated Common Stock Purchase Agreement with Keystone Capital Partners effective August 28, 2025.
Definitive proxy filed Aug 15; SEC completed review with no further comments on Aug 18.
Q2 revenue $1.2M vs $1.5M YoY; net loss from continuing ops $4.5M ($0.11/share) vs $5.5M ($0.29/share).
Special Meeting of Shareholders on August 29, 2025 to vote on increasing authorized shares to 1 billion.
ProPhase Labs raises $2.75M via senior secured convertible notes with 20% OID and warrants
Notes have $3.75M face value after 20% OID; net proceeds ~$2.75M; mature July 22, 2026.
ProPhase Labs closes $3M senior secured convertible notes with warrants at $0.50
Notes have 20% original issue discount, secured by Company assets, not convertible for first 4 months.
Board unanimously authorized exploring reverse merger with a digital asset-focused operating company (crypto treasury management).
ProPhase Labs regains Nasdaq compliance after appointing new independent director
Appointed Carolina Abenante as independent director on June 20, 2025.
ProPhase Labs enters $1M bridge loan (20% OID) from CEO and investor; issues warrants
Each loan (CEO and investor) $500k principal, 20% OID ($625k face), 10% interest, 12-month maturity.
ProPhase Q1 net loss narrows to $4.7M, cuts costs, eyes Nebula sale, $50M recovery
Q1 net revenue $1.4M (down from $2.4M YoY); net loss $4.7M ($0.13/shr) vs $5.5M loss ($0.32/shr) last year.
ProPhase Labs reports FY2024 net loss of $53.4M; revenue down 81% to $6.8M
Net revenue fell 80.6% to $6.8M from $35.0M, driven by near-zero COVID-19 testing volumes.
ProPhase Labs appoints former Barstool Sports COO Stu Hollenshead as new COO
Stuart Hollenshead appointed COO effective Feb 17, 2025, replacing Jed Latkin who resigned Feb 14.
ProPhase Labs COO Jed Latkin departing Feb 14; Stuart Hollenshead in talks to replace him
Jed Latkin, COO, leaves Feb 14, 2025, to pursue other opportunities; will consult on projects.
ProPhase Labs enters $7.73M equity line with Keystone Capital; issues 352,176 commitment shares
Up to $7,730,973 of common stock may be sold to Keystone Capital at 90% of lowest traded price or VWAP.
ProPhase Labs sells Pharmaloz subsidiaries for $2M cash and $10M debt relief
JL Projects purchased all shares of Pharmaloz Manufacturing and Pharmaloz Real Estate; transaction closed Jan 16, 2025.
ProPhase Labs receives Nasdaq bid price deficiency notice; 180-day cure period until June 24, 2025
Received Nasdaq letter on Dec 26, 2024 for bid price below $1.00 for 30 consecutive business days.
ProPhase Labs closes public offering of 4.8M shares at $0.72, raising ~$3.45M gross
Offering of 4,795,500 shares at $0.72 per share; gross proceeds $3.45M, net proceeds ~$3M.
ProPhase Labs Q3 net revenue $3.1M (down 63% YoY); net loss $6.6M ($0.35/sh)
Net revenue $3.1M vs $8.4M in Q3 2023; net loss $6.6M ($0.35/sh) vs $5.1M ($0.30/sh).
ProPhase Labs proposes public stock offering; discloses $500K term note and future receipts deals
Announced underwritten public offering of common stock and/or pre-funded warrants; no size or price disclosed.
ProPhase Labs auditor Morison Cogen resigns due to exit from PCAOB audit business
Morison Cogen resigned as independent auditor effective September 30, 2024, because it decided to exit the PCAOB audit market.
ProPhase Labs issues $10M amended promissory note at 15% interest, due 2027
Amended and restated unsecured promissory note to JXVII Trust for $10M principal, replacing $7.6M note from Jan 2023.
ProPhase increases debt to $10M at 15% interest; adds risk factor on debt service
Amended note principal increased from $7.6M to $10.0M; additional net cash of ~$2.31M after interest.
ProPhase Labs Q2 revenue falls 81% to $2.5M; net loss $(0.33) per share; eyes H2 growth
Net revenue $2.5M vs $13.2M YoY; net loss $6.2M ($0.33 per share) vs $3.4M ($0.20) in Q2 2023.
On June 20, 2025, the Board of Directors (the “Board”) of ProPhase Labs, Inc. (the “Company”) appointed Carolina Abenante, Esq. to serve as an independent director to fill the existing vacancy on the Board.
On February 18, 2025, ProPhase Labs, Inc. (the “Company”) announced that Stuart Hollenshead has been appointed to serve as Chief Operating Officer of the Company, effective on February 17, 2025, to replace Jed Latkin, who as previously reported, stepped down as Chief Operating Officer effective February 14, 2025 to pursue other business opportunities.
On February 18, 2025, ProPhase Labs, Inc. (the “Company”) announced that Stuart Hollenshead has been appointed to serve as Chief Operating Officer of the Company, effective on February 17, 2025, to replace Jed Latkin, who as previously reported, stepped down as Chief Operating Officer effective February 14, 2025 to pursue other business opportunities.
ProPhase Labs, Inc. (the “Company”) is in final stages of negotiation with Stuart Hollenshead to be the new Chief Operating Officer of the Company.
Jed Latkin, Chief Operating Officer of the Company, provided notice to the Company on February 7, 2025, that he would be leaving the Company effective February 14, 2025 to pursue other business opportunities.
On September 20, 2024, Eleanor McBrier notified the Board of her intention to resign as director of the Company, effective immediately.
Mr. Latkin was appointed to serve as Chief Operating Officer of the Company, effective on January 1, 2024.
Robert A. Morse mutually agreed that Mr. Morse would cease to be Chief Financial Officer of the Company and resume his role as Controller of the Company, effective January 1, 2024,
Jed A. Latkin has been appointed to serve as Chief Operating Officer of the Company, effective on January 1, 2024.
On April 4, 2023, Robert A. Morse, Jr. was promoted to the position of Chief Financial Officer of ProPhase Labs, Inc. (the “Company”).
Robert A. Morse, Jr., Controller of the Company, will assume the role of principal financial officer and principal accounting officer of the Company as of the Effective Date.
On December 23, 2022, Monica Brady, Chief Accounting Officer of ProPhase Labs, Inc. (the “Company”), provided notice to the Company that she would be leaving the Company effective January 13, 2023 (the “Effective Date”) to pursue other business opportunities.
Max materiality 0.90 · Median 0.60 · Most common event other_material